NCT05666700View on ClinicalTrials.gov

CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 8, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Extramedullary Myeloma
Interventions
BIOLOGICAL

Combination Product: JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent

Cilta-cel is a cellular immunotherapy derived from autologous CD3+ T-cells that have undergone ex vivo modification to target B-Cell Maturation Antigen (BCMA) on the surface of plasma cells. Cilta-cel will be administered as two IV infusions, ≥70% unlabeled and ≤30% labelled. The dose will be based on the patient's weight (kg) at apheresis

Trial Locations (1)

3000

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

All Listed Sponsors
collaborator

Janssen, LP

INDUSTRY

lead

Peter MacCallum Cancer Centre, Australia

OTHER